Add like
Add dislike
Add to saved papers

Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.

BACKGROUND: Breast cancer (BC) is regarded as a heterogeneous disease that is classified into various molecular subtypes using gene expression analysis. The aim of this study was to perform a population-based analysis of the prevalence of molecular BC subtypes in Turkish women, and to determine their association with known prognostic and clinicopathological factors.

PATIENTS AND METHODS: A total of 1,025 cases with operable BC, who presented within a 2 year period (2006-2007), were evaluated. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression were determined immunohistochemically.

RESULTS: 68.3% of patients were ER-positive, and 71.5% were PR-positive. Among the 28.3% of HER2-positive tumors, the majority (19.2%) stained +++. Almost 50% of the tumors were ER+ PR+ HER2-, which makes this the predominant tumor type. For both triple-negative and positive status, a ratio of approximately 10% was determined. For ER+ PR+ HER2-, tumor histology, tumor stage, and histological grade were found to be correlated. Menopausal status, obesity, tumor histology, histological grade, in-situ component, and lymphovascular invasion were associated with triple-positive tumors. A significant relationship was found between the variables - including histological grade, in-situ component, and involvement of axillary lymph nodes - and triple-negative status.

CONCLUSION: A more thorough understanding of the biological background and underlying mechanisms of BC may allow the development of rational targeted approaches and therapies.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app